Short answer
PROTHENA CORP PUBLIC LTD CO (PRTA) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $51M (up 1706.4% year over year) with net income of $33M.
Q1 2026 key financials · XBRL
- Revenue
- $51M
- +1706.4% YoY
- Net income
- $33M
- +154.4% YoY
- Operating margin
- 58.8%
- EPS (diluted)
- $0.60
- +153.6% YoY
Source: XBRL data from the PROTHENA CORP PUBLIC LTD CO (PRTA) Q1 2026 10-Q on SEC EDGAR. USD.
PROTHENA CORP PUBLIC LTD CO Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No off-balance-sheet arrangements as of March 31, 2026
- Contractual obligations $19.2M, including operating leases $8.3M and restructuring obligations $8.6M
- Restructuring cash obligations increased $0.8M for termination benefits
- Expected 2026 net cash used in operating and investing activities $18M–$23M
- Future cash requirements: discovery and pre-clinical programs, human capital, and intellectual property
Risk Factors
- New or changed risk: no material changes stated; filing directs investors to the 2025 Form 10-K risk discussion
- Liquidity risk: $329.5 million cash at March 31, 2026, with additional capital anticipated for development and commercialization
- Financial concentration risk: uninsured deposits may exceed the $250,000 FDIC limit at U.S. banking institutions
- Regulatory and compliance risk: EU GDPR penalties up to the greater of €20 million or 4% of global annual turnover
- Operational risk: cyberattacks could compromise clinical-trial data and delay regulatory approval efforts
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PROTHENA CORP PUBLIC LTD CO quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.